Crossject Total Assets
Crossject total assets. Based on the latest financial reports, Crossject (ALCJ) holds total assets worth €30.43 Million EUR (≈ $35.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Crossject worth for the company's overall valuation and market capitalisation.
Total Assets of Crossject (2010–2025)
Total assets of Crossject from 2010 to 2025. This chart illustrates how Crossject's total assets have evolved over time, based on quarterly financial data. See Crossject stock price for real-time trading data and today's change.
Crossject - Asset Composition Analysis
Crossject Total Assets Breakdown (December 2025)
Crossject total assets breakdown as of December 2025. Crossject's total assets of €30.43 Million consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 16.7% |
| Accounts Receivable | €5.89 Million | 19.4% |
| Inventory | €3.49 Million | 11.5% |
| Property, Plant & Equipment | €5.92 Million | 19.4% |
| Intangible Assets | €8.09 Million | 26.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Crossject's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ALCJ net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crossject's current assets represent 50.7% of total assets in 2025, a decrease from 60.4% in 2010.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2025, up from 10.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 22.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 26.6% of total assets.
Crossject Competitors by Total Assets
Key competitors of Crossject based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.76 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Medeon Biodesign
TWO:6499
|
Taiwan | NT$1.55 Billion |
|
ZENTEK LTD.
F:ZAY0
|
Germany | €17.38 Million |
Crossject - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.35 | 2.31 | 2.01 |
| Quick Ratio | 1.82 | 1.81 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.02 |
| Working Capital | €8.87 Million | €9.01 Million | €9.21 Million |
Crossject - Advanced Valuation Insights
This section examines the relationship between Crossject's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 40.53 |
| Latest Market Cap to Assets Ratio | 2.56 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | €30.43 Million |
| Market Capitalization | $77.81 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Crossject's assets at a significant premium (2.56x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Crossject's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Crossject (2010–2025)
The table below shows the annual total assets of Crossject from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €30.43 Million ≈ $35.58 Million |
-3.60% |
| 2024-12-31 | €31.57 Million ≈ $36.91 Million |
+10.22% |
| 2023-12-31 | €28.64 Million ≈ $33.48 Million |
-12.84% |
| 2022-12-31 | €32.86 Million ≈ $38.42 Million |
+4.23% |
| 2021-12-31 | €31.52 Million ≈ $36.86 Million |
-6.15% |
| 2020-12-31 | €33.59 Million ≈ $39.27 Million |
+37.13% |
| 2019-12-31 | €24.49 Million ≈ $28.64 Million |
+21.51% |
| 2018-12-31 | €20.16 Million ≈ $23.57 Million |
+13.79% |
| 2017-12-31 | €17.72 Million ≈ $20.71 Million |
+24.33% |
| 2016-12-31 | €14.25 Million ≈ $16.66 Million |
+2.67% |
| 2015-12-31 | €13.88 Million ≈ $16.23 Million |
-24.46% |
| 2014-12-31 | €18.37 Million ≈ $21.48 Million |
+225.23% |
| 2013-12-31 | €5.65 Million ≈ $6.60 Million |
+117.87% |
| 2012-12-31 | €2.59 Million ≈ $3.03 Million |
-10.28% |
| 2011-12-31 | €2.89 Million ≈ $3.38 Million |
+8.12% |
| 2010-12-31 | €2.67 Million ≈ $3.13 Million |
-- |
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more